COMPANY NAME	REVENUES 12 Months Ending Q3 2022	MARKET SHARE 12 Months Q3 2022	MARKET SHARE MRQ Q3 2022	MARKET SHARE A Quarter Before Q2 2022
Codiak Biosciences Inc	34.07	81.97%	9.45 %	96.14 %
Surrozen Inc	7.49	18.03%	90.55%	3.86%

CDAK's Market share relative to its competitors, as of Q3 2022 within the Biotechnology & Pharmaceuticals Industry

As of Q3 2022

COMPANY NAME	MARKET SHARE 12 Months Ending Q3 2022	MARKET SHARE 12 Months Ending Q2 2022	MARKET SHARE MRQ Q3 2022	MARKET SHARE Q2 2022
Codiak Biosciences Inc	81.97%	90.89%	9.45 %	96.14 %
Surrozen Inc	18.03%	9.11%	90.55%	3.86%

CDAK's Market share relative to its competitors, as of Q3 2022 within the Healthcare Sector

As of Q3 2022

COMPANY NAME	MARKET SHARE 12 Months Ending Q3 2022	MARKET SHARE 12 Months Ending Q2 2022	MARKET SHARE MRQ Q3 2022	MARKET SHARE Q2 2022
Codiak Biosciences Inc	81.97%	90.89%	9.45 %	96.14 %
Surrozen Inc	18.03%	9.11%	90.55%	3.86%

Note: Market share is calculated based on total revenue. To get a more accurate picture of Codiak Biosciences Inc's market divisions, geographic dispersion, segments, products, and services, visit Codiak Biosciences Inc's Business Segment.

The list includes publicly traded companies only. More information about the sources of this report can be found here.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.